News & media

The Australian Advisory Council on the Medicinal Use of Cannabis, Communiqué #21.

The Australian Advisory Council on the Medicinal Use of Cannabis, Communiqué #22.

We are updating the licence and permit variation forms for the Medicinal Cannabis Scheme.

Read the latest information on the regulation of MDMA and psilocybine.

Find out about the new fees and charges for the Medicinal Cannabis Scheme starting in August 2023.

The ODC has issued an infringement notice to the New South Wales-based company ABC CAN Pty Ltd for alleged security failures at its cannabis cultivation site.

Read about our approach to the regulated narcotic industry, and legal obligations for people with ODC licences.

The Australian Advisory Council on the Medicinal Use of Cannabis, Communiqué #20.

This public consultation is open for comment until 10 February 2023.

Welcome to the new Office of Drug Control website.

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communiqué #19.

The Office of Drug Control within the Department of Health and Aged Care has issued Queensland-based Tikun Oceana Pty Ltd an infringement notice. 

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communiqué #18.

Office of Drug Control suspends cultivation and manufacture licences of Queensland Medicinal Cannabis Licence Holder Rapid Growth Pty Ltd.

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communiqué #17.

The Amendment Act provides for amendments to the Narcotic Drugs Act 1967 to support an innovative Australian medicinal cannabis industry for the benefit of Australian patients.

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communiqué #16.

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communiqué #15

Introduction of the Narcotic Drugs Amendment (Medicinal Cannabis) Bill 2021.

On 2 December 2020, Australia voted at the Commission on Narcotic Drugs (CND) on six recommendations concerning the scheduling of cannabis and cannabis related substances, made by the World Health Organisation (WHO) in January 2019 to the CND.

The ODC is seeking comments on a review of the structure, design and administrative processes relating to medicinal cannabis related permits.

Cost recovery arrangements for cannabis-related manufacture licences and permits commenced on 1 November 2020.

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communiqué #14.

From 1 November 2020, subject to formal approval from the Federal Executive Council, cost recovery arrangements will be extended to cannabis-related manufacture licences and permits under the Medicinal Cannabis Scheme.

The Australian Advisory Council on the Medicinal Use of Cannabis (AACMC), Communiqué #13.